Currently, there are 224.29M common shares owned by the public and among those 221.22M shares have been available to trade.
The company’s stock has a 5-day price change of 5.54% and 9.33% over the past three months. INCY shares are trading -0.16% year to date (YTD), with the 12-month market performance up to 0.18% higher. It has a 12-month low price of $50.27 and touched a high of $67.36 over the same period. INCY has an average intraday trading volume of 3.06 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.03%, 12.55%, and 8.18% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Incyte Corp. (NASDAQ: INCY) shares accounts for 98.04% of the company’s 224.29M shares outstanding.
It has a market capitalization of $14.10B and a beta (3y monthly) value of 0.74. The stock’s trailing 12-month PE ratio is 19.03, while the earnings-per-share (ttm) stands at $3.29. The company has a PEG of 0.82 and a Quick Ratio of 3.43 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.00% over the week and 1.86% over the month.
Earnings per share for the fiscal year are expected to increase by 18.72%, and 21.23% over the next financial year. EPS should shrink at an annualized rate of 23.13% over the next five years, compared to 38.99% over the past 5-year period.
Looking at the support for the INCY, a number of firms have released research notes about the stock. Deutsche Bank stated their Hold rating for the stock in a research note on May 23, 2024, with the firm’s price target at $55. Leerink Partners on their part issued Outperform rating on December 13, 2023.
